IDI Kasangati (IDIK) is a leading centre dedicated to high-impact clinical research in HIV prevention in Uganda. Established with support from the University of Washington (UW) Centre for AIDS Research (CFAR), and contributions from Drs. Nick Hellman and Susan Desmond-Hellman, IDIK has a strong history of collaboration with prestigious institutions like the University of Washington, Massachusetts General Hospital, Harvard Medical School, and the University of Alabama at Birmingham.

With a focus on high-quality clinical trials, IDIK has successfully recruited and retained key populations, including adolescent girls and young women, pregnant women living with HIV and their male partners, HIV-serodifferent couples, at-risk and key populations.

To date, IDIK has conducted 37 studies funded by the US National Institutes of Health, UW CFAR, Elrha, the Gates Foundation, the Academy for Health Innovation Uganda, USAID, and the Canadian Institutes of Health Research. These studies have made significant contributions to the field of HIV prevention, particularly through the Partners PrEP and Partners in Prevention HSV/HIV Transmission Studies.

IDIK’s outstanding work in screening over 2,500 HIV-serodifferent couples and enrolling more than 1,400 couples led to high retention rates, adherence levels, and data quality. This pivotal role in the PrEP trial contributed to the approval of Truvada for oral PrEP by both the US Food and Drug Administration and the World Health Organization.